Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-07-25 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of FDA approval for a generic drug. It is a short announcement (2490 characters) focused on a regulatory approval event, not a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no management discussion, no voting results, or other regulatory filings. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-07-25 English
Lupin Receives Approval from U.S. FDA for Azilsartan Medoxomil Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a generic drug application (Azilsartan Medoxomil Tablets). It is a disclosure pursuant to SEBI Regulation 30, which relates to continuous disclosure obligations for listed companies. The document does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event, not a financial report or detailed investor presentation. The document length is 3261 characters, which is relatively short and consistent with a press release or regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like earnings release or capital update.
2022-07-25 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings Classification · 100% confidence The document text is extremely short (111 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2022-07-25 English
Disclosure pursuant to Allotment of 16772 shares under ESOP.
Share Issue/Capital Change Classification · 100% confidence The document is a letter addressed to BSE Limited regarding the allotment of shares under the Employee Stock Option Plan (ESOP). It discloses the allotment of 16,772 fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The letter references compliance with Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a capital change due to share allotment under ESOP, not a full financial report or audit. The document length is short (1246 characters), and it is clearly an update on capital structure. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-07-25 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings Classification · 90% confidence The document text is very short (555 characters) and contains fragmented information about employee stock option plans, including plan names and number of options. There is no indication of a full report, financial statements, or detailed analysis. The content resembles a brief announcement or summary related to share-based compensation or stock options. It does not fit the criteria for a full Annual Report, Interim Report, or detailed Management Report. Given the nature of the content and the short length, it is most consistent with a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-07-20 English
Intimation regarding grant of Stock Options.
Share Issue/Capital Change Classification · 95% confidence The document is a notification to the stock exchange (BSE Limited) regarding the grant of stock options to employees of subsidiary companies. It specifies the number of options granted, the exercise price, and the vesting schedule. This is an announcement related to employee stock option plans and changes in share capital structure but does not report financial results or detailed financial data. It is not a full report, earnings release, or management discussion. The document is short (1495 characters) and serves as a regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements Regulation 30, which typically covers material events including share-based payments. Therefore, the document fits best under Share Issue/Capital Change (SHA) category, as it announces issuance of stock options which can lead to share capital changes upon exercise.
2022-07-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.